Literature DB >> 1584314

Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients.

N Clyne1, T Jogestrand.   

Abstract

Anemia is already present in patients with moderate renal failure and is a major cause of the decline in exercise capacity seen in these patients. We examined the effects of erythropoietin (EPO) treatment in 12 predialytic uremic patients (EPO group: mean age 46 +/- 12 years; 6 men, 6 women) with a mean glomerular filtration rate (GFR) of 10 +/- 4 ml/min x 1.73 m2. These patients were compared to a control group of 8 patients (5 men, 3 women). The observation period was 3 months. The EPO group received 300 U/kg body weight i.v. once a week. The EPO group increased their total hemoglobin (THb) from 323 +/- 89 to 466 +/- 128 g (p less than 0.001) and their hemoglobin concentration from 86 +/- 8 to 117 +/- 11 milligrams (p less than 0.001). Their exercise capacity, measured by a standardized exercise test on a bicycle ergometer, increased from 128 +/- 45 to 147 +/- 57 W (p less than 0.01). The control group did not change their THb (349 +/- 124 and 357 +/- 131 g), hemoglobin (93 +/- 8 and 94 +/- 10 milligrams) or exercise capacity (98 +/- 49 and 101 +/- 50 W) during the observation period. There was a significant correlation between the increase in THb and the increase in exercise capacity in the EPO group (r = 0.81, p less than 0.005). The GFR was unchanged in both groups (EPO group: 10 +/- 4 and 10 +/- 6 ml/min x 1.73 m2; control group: 8 +/- 3 and 8 +/- 3 ml/min x 1.73 m2).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1584314     DOI: 10.1159/000186797

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  12 in total

1.  Quality of life in predialytic uremic patients.

Authors:  B Klang; H Björvell; N Clyne
Journal:  Qual Life Res       Date:  1996-02       Impact factor: 4.147

Review 2.  Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients.

Authors:  Deirdre Hahn; Christopher I Esezobor; Noha Elserafy; Angela C Webster; Elisabeth M Hodson
Journal:  Cochrane Database Syst Rev       Date:  2017-01-09

Review 3.  Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin?

Authors:  Farhanah Yousaf; Bruce Spinowitz
Journal:  Curr Hypertens Rep       Date:  2016-03       Impact factor: 5.369

4.  Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.

Authors:  Ioannis Koulouridis; Mansour Alfayez; Thomas A Trikalinos; Ethan M Balk; Bertrand L Jaber
Journal:  Am J Kidney Dis       Date:  2012-08-22       Impact factor: 8.860

Review 5.  Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis.

Authors:  June D Cody; Elisabeth M Hodson
Journal:  Cochrane Database Syst Rev       Date:  2016-01-20

Review 6.  High-altitude training. Aspects of haematological adaptation.

Authors:  B Berglund
Journal:  Sports Med       Date:  1992-11       Impact factor: 11.136

Review 7.  Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.

Authors:  Suetonia C Palmer; Valeria Saglimbene; Dimitris Mavridis; Georgia Salanti; Jonathan C Craig; Marcello Tonelli; Natasha Wiebe; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2014-12-08

8.  Utilization Patterns of IV Iron and Erythropoiesis Stimulating Agents in Anemic Chronic Kidney Disease Patients: A Multihospital Study.

Authors:  Avani D Joshi; David A Holdford; Donald F Brophy; Spencer E Harpe; Darcy Mays; Todd W B Gehr
Journal:  Anemia       Date:  2012-04-19

9.  Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations.

Authors:  Rebecca J Schmidt; Cheryl L Dalton
Journal:  Osteopath Med Prim Care       Date:  2007-10-02

Review 10.  Erythropoietin, a novel versatile player regulating energy metabolism beyond the erythroid system.

Authors:  Li Wang; Lijun Di; Constance Tom Noguchi
Journal:  Int J Biol Sci       Date:  2014-08-23       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.